Analysis of p53 codon 72 polymorphism and its association with human papillomavirus 16 and 18 E6 in Chinese cervical lesions

International Journal of Gynecological Cancer

Volumn 16, Issue 6, 2006, Pages 2004-2008

  Min Min, H ^a   Ming Rong, X ^a   Ze Yi, C ^a   Kai Xuan, Y ^a   Zhi Lin, S ^b  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Cervical cancer; Cervical intraepithelial neoplasm; E6; HRHPV; p53 codon 72 polymorphism

Indexed keywords

ARGININE; PROLINE; PROTEIN P53;

ADENOCARCINOMA; ADVANCED CANCER; ARTICLE; CANCER GENETICS; CANCER GRADING; CANCER RISK; CANCER STAGING; CHINESE; CODON; CONTROLLED STUDY; DNA POLYMORPHISM; EARLY CANCER; FEMALE; GENOTYPE; HETEROZYGOSITY; HIGH RISK PATIENT; HOMOZYGOSITY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN TISSUE; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; RISK FACTOR; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; VIRUS CARCINOGENESIS;

ALLELES; CHINA; CODON; DNA-BINDING PROTEINS; FEMALE; HEALTH; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; ONCOGENE PROTEINS, VIRAL; POLYMORPHISM, GENETIC; REPRESSOR PROTEINS; TUMOR SUPPRESSOR PROTEIN P53; UTERINE CERVICAL NEOPLASMS;

EID: 33845547965     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2006.00733.x     Document Type: Article

References (13)

1. Matlashewski GJ, Tuck S, Pim D et al. Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol 1987;7:961-3.
2. Storey A, Thomas M, Kalita S et al. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 1998;393:229-34.
3. Sambrook J, Fritsch EF, Maniatis TJ. Molecular cloning, a laboratory manual, 3rd edn. Cold Spring Harbor Laboratory Press, 2002;1:71-2.
4. Helland A, Langerod A et al. p53 polymorphism and risk of cervical cancer. Nature 1998;396:530-1.
5. Agnetha M, Josefsson Patrik KE et al. p53 polymorphism and risk of cervical cancer. Nature 1998;396:531.
6. Hildesheim A, Schiffman M et al. p53 polymorphism and risk of cervical cancer. Nature 1998;396:531-2.
7. Lee HP, Jeon YT et al. p53 codon 72 polymorphism and cervical adenocarcinoma risk in Korean women. Int J Gynecol Cancer 1999;10:352-6.
8. Thomas M, Massimi P, Jenkins J et al. HPV-18 E6 mediated inhibition of p53 binding activity is independent of E6 induced degradation. Oncogene 1995;10:261-8.
9. Pegoraro RJ, Rom L, Lanning PA et al. p53 codon 72 polymorphism and human papillomavirus type in relation to cervical cancer in South African women. Int J Gynecol Cancer 2002;12:383-8.
10. Purdie K. Malignant transformation of cutaneous lesions in renal allograft patients: a role for human papillomavirus. Cancer Res 1993;53:5328-33.
11. Soulitzis N, Sourvinos G, Dokianakis DN et al. P53 codon 72 polymorphism and its association with bladder cancer. Cancer Lett 2002;179:175-83.
12. McGregor JM, Harwood CA, Brooks L et al. Relationship between p53 codon 72 polymorphism and susceptibility to sun-born and skin cancer. J Invest Dermatol 2002;119:84-90.
13. Qie MR, He YD, Yang XY et al. The preliminary study on the relationship between HPV-associated cervical cancer and p53 codon 72 polymorphism in Sichuan Province. The Chinese-German Journal of Clinical Oncology 2003;2:160-2.